Loading...
XKRX
214390
Market cap80mUSD
Jul 10, Last price  
5,150.00KRW
1D
1.58%
1Q
-27.97%
Jan 2017
-63.08%
IPO
-83.91%
Name

Kyongbo Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:214390 chart
P/E
675.40
P/S
0.47
EPS
7.63
Div Yield, %
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
4.17%
Revenues
264.10b
+10.71%
169,781,246,180178,032,632,080186,726,169,860191,661,374,450201,343,595,540191,706,189,110215,285,095,000170,659,645,000196,264,902,080216,357,482,000238,556,126,000264,104,056,999
Net income
182m
-96.07%
8,635,953,72026,109,623,15012,705,929,80017,963,309,61013,116,049,3905,285,239,3909,404,446,000-7,495,179,000610,590,0902,974,400,0004,639,326,000182,293,090
CFO
7.46b
+4,899.83%
16,041,866,8704,240,141,97025,328,802,77025,805,145,560-1,138,159,26023,668,110,96020,795,227,00017,967,903,00010,126,731,0004,844,320,000149,116,0007,455,546,000
Dividend
Dec 27, 202450 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1987 and based in Asan, South Korea, Kyongbo Pharmaceutical Co., Ltd is a key player in the South Korean pharmaceutical market, primarily focusing on the production and distribution of active pharmaceutical ingredients (APIs). Its API offerings span general, cephalosporin, and anti-cancer categories. Beyond APIs, the company also supplies a range of finished pharmaceutical products, including prescription medications for anesthetic, cardiovascular, and digestive uses, as well as antibiotics, alongside its over-the-counter (OTC) drug portfolio. Kyongbo Pharmaceutical extends its reach internationally, exporting its goods to 30 countries worldwide. The company officially adopted its current name, Kyongbo Pharmaceutical Co., Ltd, in March 2002, having previously been known as Kyongbo Chemical Co. Ltd.
IPO date
Jun 29, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT